

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 October 2008 (30.10.2008)

PCT

(10) International Publication Number
WO 2008/130534 A1

(51) International Patent Classification:
C07D 491/22 (2006.01) *A61K 31/4745* (2006.01)
C07D 491/14 (2006.01)

(74) Agent: **CHENG, Kent, H.**; Cohen Pontani Lieberman &
Pavane LLP, 551 Fifth Avenue, New York, NY 10176 (US).

(21) International Application Number:
PCT/US2008/004840

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(22) International Filing Date: 14 April 2008 (14.04.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/925,280 19 April 2007 (19.04.2007) US

(71) Applicant (*for all designated States except US*):
SCINOPHARM TAIWAN LTD.; 1, Nan-ke 8th Road,
Tainan Science-based Industrial Park, Tainan County, 741
(TW).

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for LC only*): **CHEN, Hardy** [US/US]; 708
Vista Del Sol, San Mateo, CA 94404 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **HU, Tsung-Cheng**;
No. 140 Dongmen Road, Yongjing Township, Changhua
County, 512 (TW). **CHEN, Shu-Ping**; No. 56, Liaoning
2nd Street, Sanmin District, Kaohsiung City, 807 (TW).
HARN, Piin-Jye; No. 14, Lane 506, Sindu Road, South
District, Tainan City, 702 (TW). **SHIEH, Chia-Lin, Char-**
lene; No. 165, Nanhai Street, Sinsing District, Kaohsiung
City (TW).

Published:

- *with international search report*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(54) Title: CRYSTALLINE FORMS OF TOPOTECAN HYDROCHLORIDE AND PROCESSES FOR MAKING THE SAME

(57) Abstract: Novel crystalline forms of topotecan hydrochloride and processes of making the same are disclosed.



WO 2008/130534 A1

5 **Crystalline Forms of Topotecan
Hydrochloride and Processes for Making the
Same**

RELATED APPLICATIONS

10 [0001] This application claims priority from U.S. Provisional Patent Application Serial Number 60/925,280 which was filed on April 19, 2007. The entire content of U.S. Provisional Patent Application Serial Number 60/925,280 is incorporated herein by reference.


BACKGROUND OF THE INVENTION

1. Field of the Invention

[0002] The present application relates to crystalline forms of topotecan hydrochloride and processes for making the same.

2. Description of the Related Art

[0003] Topotecan hydrochloride is (10-[(dimethyl amino) methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinol-ine-3,14(4H,12H)dione hydrochloride) a compound of formula (I)



[0004] U.S. Patent No. 5,004,758 discloses water
30 soluble camptothecin analogs, which includes topotecan

5 (9-dimethylamino methyl-10-hydroxy camptothecin), preferably (S)-topotecan and its hydrochloride salt.

[0005] PCT Application No. WO2005/046608 discloses a crystalline form of topotecan monohydrochloride pentahydrate with an X-ray diffraction pattern depicted
10 in Fig. 1 therein. For the purpose of the present disclosure, this crystalline form is designated Form A.

SUMMARY OF THE INVENTION

[0006] The present invention relates to novel
15 crystalline forms of topotecan hydrochloride that have been produced using a variety of crystallization processes. These crystalline forms are designated Forms B, C, D, E, F, G, H, I, J, and K.

[0007] The crystalline forms are characterized by
20 their X-ray powder diffraction patterns and their IR spectra.

[0008] According to one aspect of the invention, there is provided a crystalline Form B of topotecan hydrochloride having an XRPD pattern with characteristic
25 peaks at 6.1, 8.1, 23.4, 25.5 and 26.3 °2 θ ($\pm 0.2^\circ$).

[0009] According to another aspect of the invention, there is provided a crystalline Form C of topotecan hydrochloride having an XRPD pattern with characteristic peaks at 6.9, 7.5, 15.1, 16.3, 25.1, and 26.0 °2 θ
30 ($\pm 0.2^\circ$). Preferably, crystalline Form C of topotecan hydrochloride has characteristic FT-IR peaks at 1754, 1723, 1658, 1597, and 1508 cm⁻¹.

[0010] According to further aspect of the invention, there is provided a crystalline Form D of topotecan
35 hydrochloride having an XRPD pattern with characteristic peaks at 5.9, 13.9, 22.6, 23.2, and 26.5 °2 θ ($\pm 0.2^\circ$).

5 Preferably, crystalline Form D of topotecan hydrochloride has characteristic FT-IR peaks at 1742, 1654, 1586, 1510, and 1467 cm^{-1} .

[0011] According to yet another aspect of the invention, there is provided a crystalline Form E of
10 topotecan hydrochloride having an XRPD pattern with characteristic peaks at 14.0, 18.8, 22.5, 25.4, and 25.7 $^{\circ}2\theta$ ($\pm 0.2^{\circ}$). Preferably, crystalline Form E of topotecan hydrochloride has characteristic FT-IR peaks at 1752, 1649, 1584, 1567, and 1513 cm^{-1} .

15 [0012] According to further aspect of the invention, there is provided a crystalline Form F of topotecan hydrochloride having an XRPD pattern with characteristic peaks at 6.7, 12.4, 24.9, 25.4, 25.7, and 26.8 $^{\circ}2\theta$ ($\pm 0.2^{\circ}$). Preferably, crystalline Form F of topotecan
20 hydrochloride has characteristic FT-IR peaks at 1740, 1655, 1590, 1507, and 1467 cm^{-1} .

[0013] According to another further aspect of the invention, there is provided a crystalline Form G of topotecan hydrochloride having an XRPD pattern with
25 characteristic peaks at 6.2, 8.1, 21.2, 23.4, 25.5, 26.3, and 28.0 $^{\circ}2\theta$ ($\pm 0.2^{\circ}$). Preferably, crystalline Form G of topotecan hydrochloride has characteristic FT-IR peaks at 1745, 1657, 1597, and 1507 cm^{-1} .

[0014] According to yet another further aspect of the invention, there is provided a crystalline Form H of
30 topotecan hydrochloride having an XRPD pattern with characteristic peaks at 6.6, 10.2, 18.7, 20.5, 25.9, and 29.2 $^{\circ}2\theta$ ($\pm 0.2^{\circ}$). Preferably, crystalline Form H of topotecan hydrochloride has characteristic FT-IR peaks
35 at 1756, 1657, 1613, and 1537 cm^{-1} .

5 [0015] According to yet another further aspect of the invention there is provided a crystalline Form I of topotecan hydrochloride having an XRPD pattern with characteristic peaks at 7.0, 10.2, 20.8, 22.1, and 27.9 °2θ (±0.2°). Preferably, crystalline Form I of
10 topotecan hydrochloride has characteristic FT-IR peaks at 1746, 1656, 1608, 1535, and 1495 cm⁻¹.

[0016] According to yet another further aspect of the invention there is provided a crystalline Form J of topotecan hydrochloride having an XRPD pattern with
15 characteristic peaks at 7.8, 10.0, 16.4, 17.0, 20.2, and 27.1 °2θ (±0.2°). Preferably, crystalline Form J of topotecan hydrochloride has characteristic FT-IR peaks at 1745, 1657, 1598, and 1508 cm⁻¹.

[0017] According to further aspect of the invention
20 there is provided a crystalline Form K of topotecan hydrochloride having an XRPD pattern with characteristic peaks at 6.0, 14.1, 22.8, 25.9, and 30.0 °2θ (±0.2°). Preferably, crystalline Form K of topotecan hydrochloride has characteristic FT-IR peaks at 1753,
25 1653, 1584, 1567, and 1512 cm⁻¹.

[0018] The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of the disclosure. For a better understanding of
30 the invention, its operating advantages, and specific objects attained by its use, reference should be had to the drawing and descriptive matter in which there are illustrated and described preferred embodiments of the invention.

35 **BRIEF DESCRIPTION OF THE DRAWINGS**

[0019] In the drawings:

- 5 [0020] FIG. 1 is a characteristic powder X-ray diffraction pattern of Form A (WO2005/046608).
- [0021] FIG. 2 is a characteristic powder X-ray diffraction pattern of Form C.
- [0022] FIG. 3 is an infrared diffuse reflectance
10 pattern of Form C.
- [0023] FIG. 4 is a characteristic powder X-ray diffraction pattern of Form D.
- [0024] FIG. 5 is an infrared diffuse reflectance pattern of Form D.
- 15 [0025] FIG. 6 is a characteristic powder X-ray diffraction pattern of Form E.
- [0026] FIG. 7 is an infrared diffuse reflectance pattern of Form E.
- [0027] FIG. 8 is a characteristic powder X-ray
20 diffraction pattern of Form F.
- [0028] FIG. 9 is an infrared diffuse reflectance pattern of Form F.
- [0029] FIG. 10 is a characteristic powder X-ray diffraction pattern of Form G.
- 25 [0030] FIG. 11 is an infrared diffuse reflectance pattern of Form G.
- [0031] FIG. 12 is a characteristic powder X-ray diffraction pattern of Form H.

5 [0032] FIG. 13 is an infrared diffuse reflectance
pattern of Form H.

[0033] FIG. 14 is a characteristic powder X-ray
diffraction pattern of Form I.

[0034] FIG. 15 is an infrared diffuse reflectance
10 pattern of Form I.

[0035] FIG. 16 is a characteristic powder X-ray
diffraction pattern of Form J.

[0036] FIG. 17 is an infrared diffuse reflectance
pattern of Form J.

15 [0037] FIG. 18 is a characteristic powder X-ray
diffraction pattern of Form K.

[0038] FIG. 19 is an infrared diffuse reflectance
pattern of Form K.

[0039] FIG. 20 is a characteristic powder X-ray
20 diffraction pattern of Form B.

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

[0040] Further, the crystalline forms in accordance
25 with some aspects of the present application have been
characterized by their water content, chloride content,
and solvent residue.

5

Form	Water Content (wt %)	Cl Content (wt %)	Solvent residue by NMR
D	9.73 9.96 9.50 (3 samples)	9.61 9.76 9.44 (3 samples)	Ethanol= Not detected Ethyl Acetate =0.73%
E	3.86 1.46 4.13 (3 samples)	7.8 8.16 (2 samples)	Ethyl Acetate =0.41%
F	18.31	7.7	Acetonitrile =1.93%
G	9.37	7.7	Methanol=1.24% Ethyl Acetate =4.57%
H	2.91	-	Methanol = 3.59% Acetonitrile =0.27%
I	4.50	-	Methanol =0.10% Acetonitrile =4.06% Ethyl Acetate =0.31%
J	-	-	Methanol =0.16% Acetonitrile =3.17% Ethyl Acetate =2.68%

"-" means the experiment is not preformed on the crystalline form.

[0041] It is easier to remove solvents from Forms D and E than from Forms F to J by drying. In addition, the water/Cl content of Form D is more stable than that of Form E.

[0042] The stabilities of some of the crystalline forms have been tested under various conditions. HPLC was used to determine the degree of degradation of topotecan hydrochloride over time.

[0043] The samples with different forms were held at room temperature for a specific period. We tested the purities of these samples by HPLC and observed the changes of their purities.

- 5 [0044] The changes to the purities of Forms D to I are summarized as follows:

(a) The change of the purity of Form D:

Duration Time	Purity
0 hour	99.32%
3 days	99.21%
7 days	99.17%
20 days	99.08%
36 days	99.43%

(b) The change of the purity of Form E:

Duration Time	Purity
0 hour	98.99%
3 days	99.27%
7 days	99.31%
20 days	99.29%
36 days	99.30%

- 10 (c) The change of the purity of Form F:

Duration Time	Purity
0 hour	99.94%
3 days	99.92%
16 days	99.91%
32 days	99.91%

(d) The change of the purity of Form G:

Duration Time	Purity
0 hour	99.11%

3 days	99.06%
7 days	99.00%
20 days	98.88%
32 Days	99.06%

5 (e) The change of the purity of Form H:

Duration Time	Purity
0 hour	99.92%
3 days	99.90%
7 days	99.92%
20 days	99.89%

(f) The change of the purity of Form I:

Duration Time	Purity
0 hour	99.70%
3 days	99.65%
7 days	99.56%
20 days	99.56%

10 [0045] The results based on HPLC peak retention times indicate that topotecan hydrochloride in crystalline Forms D to G is substantially stable over thirty days at room temperature. And topotecan hydrochloride in crystalline Forms H and I is substantially stable over twenty days at room temperature.

15 [0046] According to the above-mentioned information, the water and chloride content of Form D is more stable than that of Form E, and the solvent residue of Form D is lower than that of Forms F to J. In addition, the stability of Form D at room temperature is also better
20 than other Forms.

5 [0047] Form D was compared with Form A in the following two experiments.

Experiment 1

[0048] Topotecan hydrochloride (1.75 g), 99.5%
10 ethanol (about 12 ml), the different equivalents of water {(1)3.3, (2)4.3, (3)4.5, (4)4.7, (5)4.8, (6)5.1 ml}, and the different equivalents of 2N HCl solution {(1)1.91, (2)0.96, (3)0.76, (4)0.57, (5)0.48, (6)0.19 ml} are mixed in a suitable reactor. The mixture is then
15 heat up to about 50°C to dissolve. Ethyl acetate (about 38 ml) is added and then cools down to about 10°C and stir at this temperature for not less than (NLT) 1 hour. The solids are filtered and washed with cool ethyl acetate. Dry under vacuum at room temperature.

20 Experiment 2

[0049] Topotecan hydrochloride (4.0g Form A or Form D) is stirred in ethyl acetate (40mL) for a long time (40, 80, or 200 hours) at room temperature. The solids
25 are filtered and washed with cool ethyl acetate. Dry under vacuum at room temperature.

[0050] The results of the two experiments are summarized as follows:

Experiment No.	Results	Water Content (wt %)	Cl Content (wt %)
1	(1) 1.0eq HCl (aq)	9.96	9.76
	(pH=0.47): Form D	9.73	9.61
	(2) 0.5eq HCl (aq)	-	-
	(pH=0.9): Form D	11.61	7.69
	(3) 0.4eq HCl (aq)	16.62	7.74
	(pH=1.17): Form D	10.84	7.60
	(4) 0.3eq HCl (aq)		

	(pH=1.27): Form A (5) 0.25eq HCl (aq) (pH=1.51): Form A (6) 0.1eq HCl (aq) (pH=2-3): Form A		
2	(1) 40h: Form A→A; Form D→D (2) 80h: Form A→E; Form D→D (3) 200h: Form A→E; Form D→D	-	-

5 "-" means the water/Cl content test is not preformed on the sample.

[0051] According to the results of the above two experiments, Form D will be formed in the lower pH condition, and Form A will be formed in the higher pH condition. The water content of Form D is more stable than that of Form A under the different pH conditions for crystallizing.

[0052] Furthermore, Form D is more stable than Form A for a long time stirring before crystallizing. After stirring in ethyl acetate over 80 hours, Form A will transform to Form E. However, Form D will be stable even when being stirred in ethyl acetate over 200 hours.

[0053] The appearance, HCl content, and the capability of removing solvents by drying of Forms A and D are listed as follows:

Item	Form A	Form D
Appearance	light yellow to Yellow	Orange
Equivalent HCl content	1	1.4
To remove solvents by drying	hard	Easy

5 [0054] The HCl content of Form D is higher than that of Form A, and the solvent residue of Form D is lower than that of Form A after drying.

[0055] The following examples are provided to illustrate the process of the polymorphs of topotecan hydrochloride
10 in accordance with the present application.

Example 1

[0056] Water (7.5 kg) and acetonitrile (2.4 kg) were charged into a suitable reactor. The resulting mixture
15 was heated to about 45°C. Topotecan HCl (1.5 kg) was added into resulting mixture at about 45°C, and then acetonitrile (about 21 kg) was added into the resulting mixture. After the addition was completed, the mixture was cooled to about 10°C, stirred for not less than 30
20 minutes, and then filtered. The wet cake was then washed with acetone (about 9 kg). The wet solids were dried under vacuum to give about 1.3 kg of Topotecan HCl Form B.

25 Example 2

[0057] Topotecan HCl (1.5 kg), ethanol (about 8 kg) and water (about 4 kg) were charged into a suitable reactor. The resulting slurry was heated to about 50°C, and then filtered through silica gel and celite bed. The
30 hot (about 50°C) mixture of ethanol-water (Volume ratio: 7:3, about 2.5 kg) and ethyl acetate (about 5 kg) were added for rinse, and then cooled to about 35°C. Ethyl acetate (about 23 kg) was added into the resulting mixture. After the addition was completed, the mixture
35 was cooled to about 10°C, stirred, and then filtered. The wet cake was then washed with cold Acetone (about 9

5 kg). The wet solids were dried under vacuum to give about 0.8 kg of Topotecan HCl Form C.

Example 3

[0058] Topotecan HCl (1.75 g), ethanol (about 12 ml), and water (about 5 ml) were charged into a suitable
10 reactor. The resulting slurry was heated to about 50°C. When the mixture become to a clear solution, the solution was cooled down to about 40°C and adjusted the pH value to < 1.2 with 2N HCl (aq). Ethyl acetate (about 18 ml) was added. After the addition was finished, the
15 mixture was cooled to about 10°C and stirred for one hour. The solids were filtered and washed with cold acetone (about 14 ml). The solids were dried under vacuum to give about 1.5 g of Topotecan HCl Form D.

Example 4

20

Crystallization

[0059] Water (about 8 kg) and acetonitrile (about 2 kg) were charged into a suitable reactor. The resulting mixture was heated to about 40°C. Topotecan HCl (about
25 1.5 kg) was added into the resulting mixture, and then acetonitrile (about 21 kg) was added into the resulting mixture. After the addition was completed, the mixture was cooled to below 10°C, and then filtered. The wet cake was then washed with acetone (about 9 kg). The wet
30 solids were dried to give about 1.3 kg of topotecan HCl.

Re-crystallization

[0060] Ethanol (about 8 kg) and water (about 4 kg) were charged into a suitable reactor and heated to 35-
35 50°C, and then topotecan HCl obtained from the crystallization of example 3 (about 1.0 kg) was added

5 into the resulting mixture (Add HCl aqueous solution if
pH is greater than 1.2.), and then filtered through a
silica gel and celite bed. A mixture of ethanol/ water
(volume ratio: 7:3, about 2.5 kg) and ethyl acetate
(about 5 kg) was added for rinse and then cooled to 30-
10 45°C. Ethyl acetate (about 23 kg) was added into the
resulting mixture. After the addition was completed, the
mixture was cooled to below 10°C, and then filtered. The
wet cake was then washed with ethyl acetate (about 11
kg). The wet solids were dried to give 0.7-0.9 kg of
15 topotecan HCl Form D.

[0061] Two samples of topotecan HCl Form D produced
by Example 4 were analyzed to identify their impurity
content, water content and Cl content. The results are
summarized as follows:

Sample No.	1	2
Total impurities by HPLC	0.09%	0.09%
Water Content: Karl Fischer (wt %)	9	8
Chloride Content: Titration (wt %)	9.8	9.6

20

Example 5

Crystallization

[0062] Topotecan hydrochloride(1 g) was suspended in
15 mL of N,N-Dimethylformamide and heated up to 50°C to
25 give off-white slurry. It had been stirring for 10 min,
and then 40 mL of ethyl acetate were added. The mixture
was stirred under reflux for more 15 min, then cooled
down to room temperature in 30 min. The precipitate was
filtered and dried to give about 0.5 g of topotecan HCl.

30

5 Re-crystallization

[0063] Ethanol (about 4 g) and water (about 2 g) were charged into a suitable reactor and heated to 35-50°C, and then topotecan HCl obtained from the crystallization of example 4 (about 0.5 g) was added into the resulting mixture (Add HCl aqueous solution if pH is greater than 1.2.), and then filtered through a silica gel and celite bed. A mixture of ethanol/ water (volume ratio: 7:3, about 1.2 g) and ethyl acetate (about 2.5 g) was added for rinse and then cooled to 30-45°C. Ethyl acetate (about 11.5 g) was added into the resulting mixture. After the addition was completed, the mixture was cooled to below 10°C, and then filtered. The wet cake was then washed with ethyl acetate (about 5.5 g). The wet solids were dried to give 0.35-0.45 g of topotecan HCl Form D.

20

Example 6

[0064] Topotecan HCl (8.0 g), and about 0.04% HCl in Ethyl acetate (about 240 ml) were charged into a suitable reactor. The resulting slurry was stirred for not less than 80 hours. The solids were filtered and washed with Ethyl acetate (80 ml). The solids were dried under vacuum to give about 7 g of Topotecan HCl Form E.

Example 7

30

[0065] Topotecan HCl (about 1.6 g) and water (about 10 ml) were charged into a suitable reactor to form thick slurry, and acetonitrile (about 3 ml) was added. The resulting slurry was heated to 30-40°C. Adjusted the pH value to 2 by 2N HCl_(aq). Then the slurry was heated to about 45°C. When the solids were dissolved, acetonitrile

35

5 (about 30 ml) was added. The slurry was cooled to about 10°C and stirred for 1 hour. The solids were filtered and washed with cold acetonitrile (about 8 ml). The solids were dried under vacuum to give about 1.5 g of Topotecan HCl Form F.

10 Example 8

[0066] Topotecan HCl (2.0 g), Methanol (about 16 ml), and Water (about 4 ml) were charged into a suitable reactor. The resulting slurry was heated to about 50°C. When the solids were dissolved, ethyl acetate (about 36
15 ml) was added at room temperature. The slurry was cooled to about 10°C and stirred for 1 hour. The solids were filtered and washed with cold ethyl acetate (about 10 ml). The solids are dried under vacuum to give about 1 g of Topotecan HCl Form G.

20 Example 9

[0067] Topotecan HCl (about 1 g), 3% HCl_(g) in Methanol (about 22 ml), and acetonitrile (about 16 ml) were charged into a suitable reactor. The slurry was heated
25 to about 50°C and kept for 1 hour. Then the slurry was cooled to about 10°C and stirred for 1 hour. The solids were filtered and washed with cold ethyl acetate (about 10 ml). The solids were dried under vacuum to give about 0.8 g of Topotecan HCl Form H.

30 Example 10

[0068] Topotecan HCl (about 1.7 g), 1% HCl_(g) in Methanol (about 34 ml), and acetonitrile (about 25 ml) were charged into a suitable reactor. The slurry was
35 heated to about 50°C and ethyl acetate (about 67 ml) was added. The slurry was cooled to about 10°C and stirred

5 for 1 hour. The solids were filtered and washed with cold ethyl acetate (about 10 ml). The solids were dried under vacuum to give about 1.5 g of Topotecan HCl Form I.

Example 11

10

[0069] Topotecan HCl (about 2.0 g), Methanol (about 40 ml), and acetonitrile (about 30 ml) were charged into a suitable reactor. The slurry was heated to about 50°C and then stirred for over 30 minutes. The slurry was
15 cooled to about 10°C and stirred for 1 hour. The solids were filtered and washed with cold ethyl acetate (about 20 ml). The solids were dried under vacuum to give about 1.8 g of Topotecan HCl Form J.

Example 12

20 [0070] Topotecan HCl (about 20 g) and about 0.04% HCl in Ethyl acetate (about 600 ml) were charged into a suitable reactor. The resulting slurry was stirred for about 30 hours. The solids were filtered and washed with Ethyl acetate (about 100 ml). The solids were dried
25 under vacuum to give about 17.6 g of Topotecan HCl Form K.

[0071] Furthermore, crystallization/re-crystallization can also remove the impurities produced from the manufacturing process of topotecan HCl. When
30 the impurities contained in the crude topotecan HCl cannot be removed by crystallizing at a time, re-crystallization can be conducted on the topotecan HCl. The crystalline form of the final topotecan HCl will be certain until the last time crystallization.

35 [0072] Therefore, the above-mentioned examples and any combination thereof can be conducted on topotecan

- 5 HCl to remove impurities contained in topotecan HCl. Especially, one identified impurity, 9-hydroxymethyl-10-hydroxy-camptothecin (MW=394), which may formed during the manufacturing process of topotecan HCl and the purification process where water is present, can be removed efficiently by the processes in example 4 and 5. The 9-hydroxymethyl-10-hydroxy-camptothecin can be removed by the crystallization, and then the re-crystallization can control the target crystalline form of topotecan HCl.
- 10 [0073] Crystallizing crude topotecan HCl via dissolving it in high polar solvent system (more polar than the anti-solvent), and precipitating it after adding the low polar anti-solvent can efficiently remove 9-hydroxymethyl-10-hydroxy-camptothecin from it.
- 20 [0074] The impurity of the final topotecan hydrochloride is preferably less than 0.10% based on the total weight of the final topotecan hydrochloride.
- [0075] The invention is not limited by the embodiments described above which are presented as examples only but can be modified in various ways within the scope of protection defined by the appended patent claims.
- 25

5 CLAIMS

We claim:

1. A crystalline Form D of topotecan hydrochloride characterized by a powder X-ray diffraction pattern having peaks at 5.9, 13.9, 22.6, 23.2, and 26.5 °2θ
10 (±0.2°).
2. The crystalline Form D of claim 1 further characterized by an infrared diffuse-reflectance pattern having peaks at approximately 1742, 1654, 1586, 1510, and 1467 cm⁻¹.
- 15 3. The crystalline Form D claim 1 having substantially the same X-ray diffraction pattern as shown in FIG. 4.
4. The crystalline Form D of claim 1 having substantially the same infrared diffuse-reflectance pattern as shown in FIG. 5.
- 20 5. The crystalline Form D of claim 1 wherein the water content of Form D is 7 to 11 wt %.
6. The crystalline Form D of claim 1, wherein the chloride content of Form D is 8.5 to 10.5 wt %.
7. A crystalline Form E of topotecan hydrochloride
25 characterized by a powder X-ray diffraction pattern having peaks at 14.0, 18.8, 22.5, 25.4, and 25.7 °2θ (±0.2°).
8. The crystalline Form E of claim 7 further characterized by an infrared diffuse-reflectance
30 pattern having peaks at approximately 1752, 1649, 1584, 1567, and 1513 cm⁻¹.
9. The crystalline Form E of claim 7 having substantially the same X-ray diffraction pattern as shown in FIG. 6.

- 5 10. The crystalline Form E of claim 7 having substantially the same infrared diffuse-reflectance pattern as shown in FIG. 7.
11. A process for preparing the topotecan hydrochloride Form D of claim 1 comprising:
- 10 (a) dissolving topotecan hydrochloride in a first solvent system;
- (b) adjusting the pH of the resulting mixture of step (a) to below 1.2;
- (c) adding a volume of low polar solvent into the mixture of step (b) to form a second solvent system, wherein the first solvent system is more polar than the second solvent system; and
- 15 (d) crystallizing the topotecan hydrochloride Form D from the second solvent system.
- 20 12. The process of claim 11, wherein the first solvent system is a mixture of water miscible organic solvent and water.
13. The process of claim 11, wherein the water miscible organic solvent is a lower C1-C6 alcohol solvent.
- 25 14. A process for purifying topotecan hydrochloride, comprising:
- (a) dissolving topotecan hydrochloride into a first solvent system,
- (b) adding a volume of low polar solvent into the mixture of step (a) to form a second solvent system, wherein the first solvent system is more polar than the second solvent system; and
- 30

5 (c) crystallizing topotecan hydrochloride from the second solvent system.

15. The process of claim 14, wherein the first solvent system is selected from the group
consisting of water, dimethylformamide, dimethyl
10 sulfoxide, ethanol, methanol; and any combination thereof.

16. The process of claim 14 wherein the first solvent system is a mixture of a high polar solvent and a low polar solvent, wherein the amount of the high polar
15 solvent is greater than the amount of the low polar solvent

17. The process of claim 14, wherein the first solvent system is a mixture of ethanol and water.

18. The process of claim 14, wherein the first solvent
20 system is a mixture of water and acetonitrile.

19. The process of claim 14 wherein the first solvent system is a mixture of dimethylformamide and ethyl acetate.

25 20. The process of claim 14, wherein the low polar solvent is selected from the group
consisting of ethyl acetate, dichloromethane, toluene, acetonitrile, acetone; and any combination thereof.

21. The process of claim 14 wherein the purified
30 topotecan hydrochloride thereof has an impurity of less than 0.10% based on the total weight of the topotecan hydrochloride.

- 5 22. A topotecan hydrochloride having an impurity of less than 0.10% based on the total weight of the topotecan hydrochloride.




FIG.1
PRIOR ART





FIG.3




FIG.4




FIG.5




FIG. 6




FIG. 7





FIG.9




FIG.10










FIG.11












FIG.19

**FIG.20**

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US2008/004840**A. CLASSIFICATION OF SUBJECT MATTER***C07D 491/22(2006.01)i, C07D 491/14(2006.01)i, A61K 31/4745(2006.01)i*

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 8, C07D 491/22, C07D 491/14, A61K 31/4745

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

STN(CASLINK)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A	Chen et al. 'Studies on the polymorph of topotecan hydrochloride and its stability' In: Zhongguo Shenghua Yaowu Zazhi, 2005, 26(5), p.279-281.	22 1 - 21
X A	Vogt et al. 'A study of variable hydration states in topotecan hydrochloride' In: Journal of Pharmaceutical and Biomedical Analysis, 2006, 40(5), p.1080-1088.	22 1 - 21
X A	WO 05046608 A2 (SMITHKLINE BEECHAM CO.) 26 MAY 2005 cited in the application See page 3, figure 1-3, claims 1-28 and the entire document.	22 1 - 21
X A	US 5004758 (SMITHKLINE BEECHAM CO.) 02 APR. 1991 cited in the application See claims 1-35 and the entire document.	22 1 - 21

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

23 SEPTEMBER 2008 (23.09.2008)

Date of mailing of the international search report

23 SEPTEMBER 2008 (23.09.2008)

Name and mailing address of the ISA/KR

Korean Intellectual Property Office
Government Complex-Daejeon, 139 Seonsa-ro, Seo-
gu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

LEE, Jae Jeong

Telephone No. 82-42-481-5893



INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/US2008/004840

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 05046608 A2	26-05-2005	EP 1689400 A2	16-08-2006
		JP 2007510751 T	26-04-2007
		US 20070117832 A1	24-05-2007
US 5004758	02-04-1991	KR 9309357 B1	28-09-1993
		JP 06033268 B4	02-05-1994
		EP 0321122 A2	21-06-1989
<hr/>			